A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2024
This article has no abstract
Epistemonikos ID: b9d0efbf032160ae9aa5f2b54fb191456c0bd151
First added on: May 06, 2024